Autres langues Alligator Bioscience AB

Actions

ATORX

SE0000767188

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:42 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,925 ^SEK	+1,09 %		-9,14 %	+34,25 %

26/04	Alligator Bioscience et Orion Corporation annoncent l'exercice de l'option de développement dans le cadre de l'accord de collaboration de recherche et de licence 2021	CI
05/04	Alligator Bioscience AB (Publ) annonce que Graham Dixon et Veronica Wallin ne sont pas proposés pour une réélection au conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement	26/04
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	26/04
Last day of trading in paid subscribed units (Sw. BTU) in Alligator	18/04
Alligator publishes outcome in rights issue	09/04
Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024	08/04
Notice of annual general meeting in Alligator Bioscience AB	05/04
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	05/04
BioStock: Alligator Bioscience on the importance of prolonging life	02/04
BioStock: Alligator to maximise immuno-oncology innovation	27/03
Alligator Bioscience Announces Publication Highlighting its RUBY® Bispecific Antibody Format in the Scientific Journal "mAbs"	26/03
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	26/03
Alligator publishes supplementary prospectus	22/03
Alligator Bioscience publishes Annual Report for 2023	21/03
Alligator Bioscience : The subscription period in Alligator Bioscience's rights issue begins today	21/03
BioStock: Alligator's CEO on current development and the rights issue	21/03
The subscription period in Alligator Bioscience’s rights issue begins today	21/03
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue	15/03
Bulletin from the extraordinary general meeting in Alligator Bioscience AB	14/03
BioStock: Clinical effects observed with Alligator's 4-1BB agonist	14/03
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	07/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Alligator Bioscience AB

Actions

ATORX

SE0000767188

Autres langues

Filtres